Apart from considerations in the adjuvant situation, SATB1 could also prove to be a useful biomarker for identification of patients with borderline resectable tumours who will respond well to neoadjuvant chemotherapy, thus increasing the number of resectable tumours. This evidence concerns the gene SATB1 and neoplasm.